Product Description
Procure the rare and noteworthy Paclitaxel Injection IP 30 mg, a cytotoxic antineoplastic prepared for intravenous infusion as a pristine, clear, and odorless solution. This astonishing formulation, approved under strict IP Grade standards, is indicated for the treatment of ovarian, breast, and lung cancers. The sterile, single-dose glass vial is meticulously sealed with a flip-off cap and tamper-proof seal, ensuring excellence and safety. Intended solely for hospital or clinic oncology use, this prescription-only medicine demands expert handling due to its cytotoxic properties. Compatible with standard diluents, it remains stable and potent, making it a vital and ephemeral resource in modern cancer therapy.
Unmatched Precision and Clinical Application
Paclitaxel Injection IP 30 mg delivers a competitive advantage with its stable composition and adherence to Indian Pharmacopoeia standards. Specifically designed for intravenous infusion in cancer chemotherapy, it is highly efficient in both general and specific oncology settings, particularly hospitals. The site of application is the venous system, where its cytotoxic action targets malignant cells in ovarian, breast, and lung cancers, providing clinicians with a trusted therapeutic option.
Flexible Sample Policy and Streamlined Transactions
We offer an adaptive sample policy with reasonable charges, optimizing your expenditure while allowing valuable pre-purchase evaluation of Paclitaxel Injection IP 30 mg. Payment terms are structured for ease, ensuring swift processing for both domestic and international clients. Each unit is packaged in a robust glass vial with a flip-off cap and tamper-proof seal, securely boxed for export, guaranteeing pristine delivery and uncompromised quality at every stage.
FAQs of Paclitaxel Injection IP 30 mg:
Q: How should Paclitaxel Injection IP 30 mg be administered?
A: Paclitaxel Injection IP 30 mg must be diluted in either 0.9% Sodium Chloride Injection or 5% Dextrose Injection before being administered as an intravenous infusion by healthcare professionals in hospital or oncology settings.
Q: What specific conditions is Paclitaxel Injection IP 30 mg used to treat?
A: This medication is indicated for the treatment of ovarian cancer, breast cancer, and lung cancer, serving as a potent antineoplastic agent in cancer chemotherapy.
Q: When should Paclitaxel Injection IP 30 mg be used in therapy?
A: Paclitaxel Injection IP 30 mg is used as part of a prescribed chemotherapy regimen under the direction of an oncologist or medical specialist within hospital or clinical environments.
Q: Where should Paclitaxel Injection IP 30 mg be stored to maintain its efficacy?
A: It should be stored below 25C, protected from light, and must not be frozen to maintain its stability and integrity over its 24-month shelf life.
Q: What is the process for handling Paclitaxel Injection IP 30 mg safely?
A: Due to its cytotoxic nature, Paclitaxel Injection IP 30 mg must be handled with gloves and appropriate protective equipment to prevent exposure and ensure operator safety.
Q: What benefits does Paclitaxel Injection IP 30 mg offer healthcare professionals?
A: Paclitaxel Injection IP 30 mg offers a reliable, IP-standardized cytotoxic option with proven efficacy against several cancers, secured in a tamper-proof, sterile vial for controlled, safe use.